Professor and Vice Chair
- Department of Surgery
- Department of Biomedical Engineering
Dr. Aijun Wang is a Chancellor's Fellow, Professor of Surgery and of Biomedical Engineering at the University of California, Davis (UC Davis). He is the Vice Chair for Translational Research, Innovation and Entrepreneurship for the Department of Surgery, Co-Director of the Center for Surgical Bioengineering, and Dean's Fellow in Entrepreneurship at the UC Davis School of Medicine. He is also a Principal Investigator at the Institute for Pediatric Regenerative Medicine (IPRM) / Shriners Hospitals Pediatric Research Center, Northern California.
Dr. Wang received his Ph.D. in biology from Tsinghua University, Beijing, China, and underwent postdoctoral training at the UC Berkeley Department of Bioengineering and Berkeley Stem Cell Center, with a postdoctoral fellowship from California Institute for Regenerative Medicine (CIRM). He has been a faculty member of UC Davis since 2012.
Dr. Wang's research focuses on developing tools and technologies that combine molecular, cellular, tissue and biomaterial engineering to promote regeneration and restore function. The Wang Group engineers and develops stem cells, extracellular vesicles/nanomedicine and extracellular matrix/biomaterial scaffolds for the treatment of surgical conditions and diseases. The Wang Lab develops and utilizes experimental and naturally-occurring disease models to evaluate regenerative products for accelerated translational application. The Wang Lab also produces clinical-grade stem cell products, carries out investigational new drug (IND)-enabling studies required by the U.S. Food and Drug Administration (FDA) for clinical applications, and conducts human clinical trials.
Dr. Wang has been serving as PI on several major grants supported by NIH/NICHD, NIH/NINDS, the California Institute for Regenerative Medicine (CIRM), the University of California Center for Accelerated Innovation (UC-CAI), the Tobacco-Related Disease Research Program of California (TRDRP), Shriners Hospital for Children and other foundations. Dr. Wang has filed more than 20 US and international patent applications, published over 140 peer-reviewed papers and has received numerous awards, such as the UC Davis Health Deans’ Team Award for Excellence in Research, UC Davis Health Deans’ Fellowship, UC Davis School of Medicine Cultivating Team Science Award, UC Davis Chancellor's Fellowship, Deloitte QB3 Award for Innovation, the Tony Phillips Research Award from the Children’s Miracle Network (CMN), the Basil O’Connor Starter Scholar Research Award from the March of Dimes Foundation, the NIH/NHLBI Technology Development Award, the KidneyX: Redesign Dialysis Phase 2 Innovation award from the American Society of Nephrology (ASN) and the Department of Health and Human Services (HHS), and Sacramento Region Innovation Award.
- 2022 University of California Davis School of Medicine - Cultivating Team Science Award
- 2021 Sacramento Region Innovation Award
- 2020 KidneyX: Redesign Dialysis Phase 2 Award- The American Society of Nephrology (ASN) and the Department of Health and Human Services (HHS)
- 2020 University of California Davis Chancellor’s Fellow
- 2020 University of California Davis Health Deans’ Team Award for Excellence in Research
- 2018 University of California Davis School of Medicine Dean’s Fellow in Entrepreneurship
- 2017 NIH/NHLBI Technology Development Award, University of California Center for Accelerated Innovation (UC-CAI)
- 2016 The March of Dimes Foundation Basil O’Connor Starter Scholar Research Award
- 2015 Marquis Who’s Who in America 2015 (69th Edition)
- 2014 The Children’s Miracle Network (CMN) Tony Phillips Research Award
- 2014 Best of ASH (American Society of Hematology), 2014 Annual Meeting
- 2012 California Institute for Quantitative Bioscience (QB3) Deloitte QB3 Award for Innovation
- Quarter at Aggie Square
- Surgical Bioengineering (First Year Seminar)
- Stem Cell Engineering and Genetic Engineering (First Year Seminar)
- SUR199 (Surgical Lab Research)
- Stem Cell Biology and Engineering
- Extracellular Vesicle-based Theranostics
- Extracellular Matrix-based Medical Device Design and Engineering
- Tissue Regeneration and Translational Medicine
- Investigational New Drug (IND) and Investigational Device Exemption (IDE) enabling studies
- Clinical Trials in Both Human and Companion Animal Patients